Eyebright Medical Technology (Beijing) Co., Ltd. (SHA:688050)

ASLAN Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	342.33	363.9	536.66	354.9	472.87	536.84
Short-Term Investments	-	-	-	-	480	450
Trading Asset Securities	153.11	132.27	20.12	481.97	0.48	0.28
Cash & Short-Term Investments	495.44	496.17	556.78	836.86	953.35	987.12
Cash Growth	32.87%	-10.89%	-33.47%	-12.22%	-3.42%	402.79%
Accounts Receivable	382.13	353.15	212.82	103.52	67.8	74.22
Other Receivables	11.15	5.34	6.03	3.71	6.57	4.69
Receivables	393.28	358.49	218.85	107.23	74.37	78.91
Inventory	290.37	272.63	181.35	78.83	56.02	59.07
Prepaid Expenses	-	-	-	-	0.15	1
Other Current Assets	60.13	53.34	65.89	38.36	34.83	20.08
Total Current Assets	1,239	1,181	1,023	1,061	1,119	1,146
Property, Plant & Equipment	1,502	1,503	1,257	674.21	558.69	267.13
Long-Term Investments	170.54	207.83	157.44	153.56	102.16	40.78
Goodwill	139.11	139.11	132.6	21.13	21.13	-
Other Intangible Assets	209.22	190.43	174.21	107.04	91.39	90.92
Long-Term Deferred Tax Assets	80.35	72.89	46.74	29.91	34.35	25.12
Long-Term Deferred Charges	139.22	149.56	105.72	60.83	67.49	49.57
Other Long-Term Assets	56.84	36.85	149.43	120.81	45.49	18.83
Total Assets	3,536	3,497	3,062	2,244	2,048	1,639
Accounts Payable	53.69	56.08	49.05	13.86	5.57	2.18
Accrued Expenses	36.47	55.74	50.87	42.59	31.82	17.97
Short-Term Debt	-	-	25.55	-	-	-
Current Portion of Long-Term Debt	83.56	80.83	92.39	-	-	-
Current Portion of Leases	-	4.71	-	-	-	-
Current Income Taxes Payable	17.96	3.77	2.31	13.5	6.99	4.1
Current Unearned Revenue	6.91	11.46	12.6	6.47	6.16	3.41
Other Current Liabilities	78.02	86.32	145	71.29	88.88	49.43
Total Current Liabilities	276.61	298.91	377.77	147.71	139.42	77.09
Long-Term Debt	528.91	513.13	287.44	149.77	143.37	-
Long-Term Leases	24.49	10.23	13.85	13.02	11.48	-
Long-Term Unearned Revenue	21.38	22.35	10.53	8.9	10.76	12.62
Long-Term Deferred Tax Liabilities	16.33	16.26	15.14	4.26	0.8	-
Other Long-Term Liabilities	2.4	1.82	1.13	0.64	1.63	1.18
Total Liabilities	870.1	862.71	705.85	324.3	307.46	90.89
Common Stock	189.54	189.54	105.25	105.18	105.14	105.14
Additional Paid-In Capital	1,142	1,197	1,325	1,311	1,318	1,305
Retained Earnings	1,134	1,037	699.81	444.01	250.23	107.74
Treasury Stock	-20.04	-20.04	-	-	-	-
Comprehensive Income & Other	2.35	6.33	-	-	-	-
Total Common Equity	2,448	2,409	2,130	1,860	1,674	1,518
Minority Interest	217.94	224.76	226.3	59.96	66.29	29.53
Shareholders' Equity	2,666	2,634	2,356	1,920	1,740	1,548
Total Liabilities & Equity	3,536	3,497	3,062	2,244	2,048	1,639
Total Debt	636.96	608.9	419.23	162.79	154.85	-
Net Cash (Debt)	-141.51	-112.73	137.55	674.07	798.5	987.12
Net Cash Growth	-	-	-79.59%	-15.58%	-19.11%	402.79%
Net Cash Per Share	-0.75	-0.60	0.72	3.56	4.22	6.13
Filing Date Shares Outstanding	189.54	189.54	189.45	189.32	189.25	189.25
Total Common Shares Outstanding	189.54	189.54	189.45	189.32	189.25	189.25
Working Capital	962.62	881.72	645.1	913.59	979.3	1,069
Book Value Per Share	12.92	12.71	11.24	9.83	8.84	8.02
Tangible Book Value	2,100	2,080	1,823	1,732	1,561	1,427
Tangible Book Value Per Share	11.08	10.97	9.62	9.15	8.25	7.54
Buildings	-	879.35	676.61	414.46	150.37	136.27
Machinery	-	874.05	618.13	232.76	155.95	102.28
Construction In Progress	-	52.88	154.26	120.6	318.44	81

Source: S&P Global Market Intelligence. Standard template. Financial Sources.